SenzaGen receives new order of SEK 0.5 m from a recurring customer

SenzaGen has received an order for the allergy test platform GARD® valued at approximately SEK 0.5 million. The order is from a recurring customer with its own product development facility. Deliveries are planned to take place gradually during 2019.

The order includes SenzaGen's animal-free tests to assess whether chemical substances in products can cause allergic reactions to skin (GARD™skin) and in the respiratory tract (GARD™air). SenzaGen is the only company that can offer a test for respiratory allergies GARD™air. The customer will use the tests during product development to investigate whether chemical substances in their products could be allergenic. The combination of the two tests makes it possible to avoid substances with varying allergenic effects.

The order confirms that SenzaGen's animal-free method plays an important role for customers with their own product development pipeline, and specifically proves the great interest in GARD™air. The global industry for risk assessment of chemical substances seeks alternative testing methods that are more precise, ethical, provide more information, and in the long run cost-effective.

“This is a strategically important order from a customer who previously evaluated us and is now ordering a larger number of tests. The combination of skin and respiratory allergy tests is a unique offer on the market and gives customers a more comprehensive risk assessment with the possibility to identify risk of varying types of allergies. With a growing interest in our animal-free method and orders that increase in size, we look forward to continuing to contribute to the development of safe everyday products”, says Anki Malmborg Hager, CEO of SenzaGen.

SenzaGen’s GARD® product portfolio consists of a set of allergy tests with industry leading performance and accuracy. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence and replace animal experiments on whether chemical substances in products can be allergenic for the cosmetics, chemical and pharmaceutical industries.

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: | Telephone: +46 768 284822

Tina Dackemark Lawesson, Director Investor Relations & Corporate Communications
Email: | Telephone: +46 708 202944

This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above on May 17, 2019, at 8.30.

About GARD®
GARD® consists of a group of tests for analyzing chemicals’ ability to create an allergic reaction in humans. By analyzing hundreds of markers, GARD™ generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today’s standard method using mice, which only achieves 70-75 percent precision. SenzaGen’s test can also quantify the allergenic potential of a chemical substance.

About SenzaGen AB (publ)
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. The tests are sold via licensed laboratories (CRO) and distributors, and via the headquarters in Lund and the sales office in the US. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the USA. For more information visit

SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399, is the company’s Certified Adviser.